Surepharm is a contract development manufacturing organisation (CDMO) with capabilities in both the pharmaceutical and vitamin, mineral and supplements (VMS) markets. The Company specialises in producing solid dose tablets, manufacturing and packaging over 800 million tablets per year.
Souter Investments completed its investment into Surepharm in January 2022 as part of a syndicate led by Chiltern Capital, a private equity investor in the UK lower mid market.
Chiltern will work with the new management team, led by Richard Yarwood who joins as Chair, to expand Surepharm’s manufacturing and packaging capabilities as well as pursue opportunities in the high value formulation and development space. The investment will also be used to establish a sales and marketing function that will enhance Surepharm’s brand and showcase the business’ capabilities in the market. There is also the opportunity to undertake M&A which could accelerate the entry into earlier phases of the drug lifecycle and the addition of new capabilities.